HCAN:PA:PA-HSBC MSCI Canada UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 24.547

Change

+0.29 (+1.18)%

Market Cap

USD 0.03B

Volume

457.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

N/A

USD 55.36B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+3.50 (+0.60%)

USD 14.29B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+1.55 (+0.37%)

USD 13.82B
WRD:PA HSBC MSCI World UCITS ETF

+0.23 (+0.63%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+1.48 (+0.58%)

USD 9.11B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+5.00 (+0.98%)

USD 8.92B
WLD:PA Lyxor UCITS MSCI World D-EUR

+2.01 (+0.55%)

USD 7.99B
HHH:PA HSBC S&P 500 UCITS ETF

+0.28 (+0.48%)

USD 7.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.12 (+0.59%)

USD 6.91B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

+0.91 (+0.55%)

USD 5.17B

ETFs Containing HCAN:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.50% 62% D 60% D-
Dividend Return 0.99% 44% F 42% F
Total Return 5.49% 66% D+ 64% D
Trailing 12 Months  
Capital Gain 20.23% 72% C 78% C+
Dividend Return 3.45% 69% C- 60% D-
Total Return 23.68% 81% B- 82% B
Trailing 5 Years  
Capital Gain 44.70% 63% D 73% C
Dividend Return 12.89% 59% D- 51% F
Total Return 57.59% 71% C- 75% C
Average Annual (5 Year Horizon)  
Capital Gain 12.54% 69% C- 70% C-
Dividend Return N/A 63% D 53% F
Total Return N/A 28% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) N/A 55% F 57% F
Risk Adjusted Return N/A 58% F 50% F
Market Capitalization 0.03B 11% F 28% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.